Preparation, Storage and Administration of KEYTRUDA® …
WEBKEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
KEYTRUDA® (pembrolizumab) - Official Site
WEBKEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy medicines carboplatin and paclitaxel, and then KEYTRUDA may be used alone, in adults: when your cancer has spread (advanced), or; if your cancer has returned. KEYTRUDA may be used alone in ...
Prescribing Information (PI) - keytrudahcp.com
WEBView or download the Prescribing Information below, an interactive version will be available soon.
WEBKEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. (1.1) Non-Small Cell Lung Cancer...
WEBKEYTRUDA is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%)] as...
WEBKEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma • for the treatment of patients with unresectable or metastatic melanoma. (1.1) • for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. (1.1)
WEBKEYTRUDA is a programmed death receptor-1 (PD-1)-blocking . antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. (1.1) for the adjuvant treatment...
FDA approves pembrolizumab with chemotherapy for primary …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
KEYTRUDA (Merck Sharp & Dohme LLC): FDA Package Insert
WEBAug 7, 2024 · KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Skip to content